Intestinal Research 2017; 15(3): 263-265  
Could adalimumab be used safely and effectively in intestinal Behçet’s disease refractory to conventional therapy?
Jihye Park, Jae Hee Cheon
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
Correspondence to: Jae Hee Cheon, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  Tel: +82-2-2228-1990, Fax: +82-2-393-6884, E-mail: geniushee@yuhs.ac
Received: March 13, 2017; Revised: March 14, 2017; Accepted: March 16, 2017; Published online: July 30, 2017.
© Korean Association for the Study of Intestinal Diseases. All rights reserved.

Abstract
Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial


This Article

e-submission

Archives

Official Journal of

Indexed/Covered by